Enterprise Value
442.3M
Cash
442.9M
Avg Qtr Burn
-31.74M
Short % of Float
21.07%
Insider Ownership
25.48%
Institutional Own.
72.75%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tovorafenib (DAY101) Details Glioma, Solid tumor/s, Cancer | PDUFA Approval decision | |
Tovorafenib (DAY101) +/- Pimasertib Details Solid tumor/s, Cancer | Phase 2 Update |